Track market-moving stories before they get noisy

Key Takeaways VEEV expands its IQV partnership, adding clinical operations applications as enterprise standards for studies.Veeva's CTMS, eTMF, Study Startup and Site Connect tools aim to improve trial efficiency.VEEV's expanded collaboration could drive broader adoption and cross-selling. Veeva Systems (VEEV - Free Report) recently expanded its partnership with IQVIA (IQV - Free Report) , with the latter selecting additional Veeva clinical operations applications as enterprise standard solutions across its clinical development studies. The agreement builds on the companies’ previously announced electronic data capture (EDC) partnership and strengthens their collaboration in clinical research.

The expanded partnership is an encouraging development for Veeva, as IQVIA’s selection of its clinical operations applications as enterprise standards strengthens the company’s presence in clinical research technology.

Veeva has also continued to expand its customer relationships, with recent partnerships involving Servier and Amgen underscoring demand for its cloud-based solutions across the life sciences industry.

These developments could support broader adoption of Veeva’s clinical applications and strengthen its competitive position over the long term. However, the IQVIA agreement's contribution to revenue growth and profitability will depend on implementation timelines and subsequent customer demand.

Likely Trend of VEEV Stock Following the NewsFollowing the announcement, shares of VEEV traded flat in yesterday’s trading. Year to date, shares of the company have gained 35.1% compared with the industry’s 19.1% growth. However, the S&P 500 has risen 13.8% in the same timeframe.

The expanded partnership with IQVIA is likely to support VEEV’s long-term growth by strengthening the adoption of its clinical applications across a major clinical research organization. Making Veeva’s solutions standard applications for IQVIA’s clinical development studies could increase product visibility, deepen its presence in the clinical research ecosystem and create opportunities to reach more biopharmaceutical customers. The collaboration also strengthens the value proposition of Veeva’s clinical technology portfolio by enabling deeper integration and more efficient workflows.

VEEV currently has a market capitalization of $47.9 billion.

Image Source: Zacks Investment Research

More on Veeva’s Clinical Operations Software SuiteVEEV is expanding its role in clinical research by being selected as the enterprise-standard solution for IQVIA’s clinical development studies. The agreement covers Veeva Clinical Trial Management System (CTMS), electronic Trial Master File (eTMF), Study Startup and Site Connect, extending the companies’ previously announced EDC partnership. These applications are designed to support key stages of clinical trials, from study planning and site activation to trial management and documentation.

Their adoption across IQVIA’s clinical development activities is expected to support more connected workflows, improve operational efficiency and strengthen coordination among clinical research stakeholders. The collaboration also builds on the companies’ complementary capabilities, with IQVIA emphasizing that customers will retain flexibility in selecting electronic data capture, randomization and trial supply management and electronic clinical outcome assessment technologies.

Expanded Collaboration Could Strengthen Veeva’s Market PositionThe partnership could provide Veeva with a broader channel to market its clinical applications to biopharmaceutical companies that rely on IQVIA for clinical research services. IQVIA’s selection of multiple Veeva applications as enterprise standards may also strengthen customer confidence in the company’s technology and encourage sponsors to consider adopting a wider range of its solutions.

In addition, IQVIA will make Veeva’s full clinical solution portfolio available to sponsors seeking an integrated technology stack, creating a potential avenue for cross-selling. The collaboration is aimed at improving trial efficiency, strengthening clinical site engagement and enabling better-informed decisions through more connected technology workflows.

Over the longer term, these factors could support broader product adoption and recurring revenue growth for Veeva.

However, the companies have not disclosed financial terms or a deployment timeline, making the eventual revenue contribution difficult to quantify at this stage.

Industry Prospects Favoring the MarketPer a report by Grand View Research, the global healthcare CRM market size was valued at $21.5 billion in 2025 and is projected to grow from $23.3 billion in 2026 to $35.7 billion by 2033, at a CAGR of 6.2% from 2026 to 2033.

The rising demand for structured data and automation in healthcare organizations is expected to drive market growth.  

Other NewsVEEV continues to strengthen its position in the life sciences software market as the Veeva DQS platform expands reach across clinical trials. The company said the solution now supports data cleaning across more than 1,000 studies involving over 1 million subjects, highlighting growing adoption of its clinical data management capabilities.

The expanding scale of Veeva DQS is encouraging as biopharma companies increasingly prioritize efficient data management amid rising clinical trial complexity.

VEEV’s Zacks Rank & Key PicksCurrently, VEEV has a Zacks Rank #3 (Hold).

Some better-ranked stocks from the broader medical space are OPKO Health (OPK - Free Report) and Merit Medical Systems (MMSI - Free Report) .

OPKO Health, currently flaunting a Zacks Rank #1 (Strong Buy), reported a second-quarter 2026 adjusted loss of 1 cent per share, which surpassed the Zacks Consensus Estimate by 87.5%. Revenues of $163.6 million beat the Zacks Consensus Estimate by 24.7%. You can see the complete list of today’s Zacks #1 Rank stocks here.

OPK has an estimated earnings growth rate of 23.3% for 2026. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 95.1%.

Merit Medical Systems, carrying a Zacks Rank #2 (Buy) at present, reported second-quarter 2026 adjusted EPS of $1.19, which beat the Zacks Consensus Estimate by 23.9%. Revenues of $418.8 million surpassed the Zacks Consensus Estimate by 3.5%.

MMSI has an estimated long-term earnings growth rate of 10.4%. MMSI’s earnings surpassed estimates in the trailing four quarters, with the average surprise being 14.1%.

Key Takeaways More than 175 emerging biotech companies have adopted Veeva Basics to streamline drug development operations.VEEV's pre-configured applications help smaller biotechs simplify clinical, regulatory and quality processes.Veeva Basics could drive recurring revenue growth as biotech customers expand operations & technology needs.
Veeva Systems (VEEV - Free Report) recently announced that more than 175 emerging biotechnology companies are using Veeva Basics to establish their technology infrastructure and streamline drug development operations. The growing adoption highlights the company’s efforts to expand its presence among early-stage biotechs.

From an investor’s perspective, increasing adoption among emerging biotechs could support Veeva Systems’ long-term growth by building customer relationships early and creating opportunities to expand as these companies advance toward commercialization. However, the financial impact will depend on continued customer adoption and the ability to convert this momentum into meaningful revenue growth.

Likely Trend of VEEV Stock Following the NewsFollowing the announcement on Sept. 30, shares of VEEV traded flat on Oct. 7. Year to date, shares of the company have gained 32.5% compared with the industry’s 19.1% growth. However, the S&P 500 has risen 13.8% in the same timeframe.

The growing adoption of Veeva Basics could strengthen Veeva Systems’ long-term growth prospects by helping it establish relationships with emerging biotechs early in their development cycles. As these companies advance clinical programs and move toward commercialization, they may require additional applications across regulatory, quality, clinical and commercial functions, creating opportunities for Veeva Systems to expand its customer relationships and recurring revenues.

The platform’s pre-configured applications may also lower adoption barriers for smaller biotechs, broadening Veeva Systems’ addressable market and reinforcing its position in the life sciences software industry. However, the long-term benefits will depend on customer retention, expansion opportunities and the pace at which these biotechs scale their operations.

VEEV currently has a market capitalization of $47.95 billion.

Image Source: Zacks Investment Research

Veeva Basics Streamlines Operations for Emerging BiotechsVeeva Basics is designed to help emerging biotechnology companies establish a technology infrastructure without the complexity and costs associated with building customized systems. Built on VEEV’s Vault Platform, the offering provides pre-configured and pre-validated applications across clinical, regulatory, quality, medical and commercial functions. According to the company, customers can implement these applications in weeks and expand their capabilities as the businesses grow.

This approach is particularly relevant for smaller biotechs with limited IT resources that need to maintain compliance while advancing drug development programs. Whitehawk Therapeutics, for instance, highlighted improvements in regulatory and quality processes after replacing paper-based workflows with Veeva Systems solutions, while Structure Therapeutics reported better quality control and faster regulatory timelines after bringing submission publishing in-house.

Regulatory Publishing Moves In-HouseA key development is the growing use of Veeva Submissions Publishing Basics, which enables biotech companies to prepare regulatory submissions and manage interactions with health authorities internally rather than relying entirely on external service providers. For companies preparing their first submissions to the FDA, the application is designed to improve visibility and control throughout the regulatory process.

Structure Therapeutics cited better quality control and faster regulatory timelines following the adoption of the solution. By helping smaller biotechs manage complex regulatory requirements more efficiently, VEEV is addressing an important operational challenge in drug development. The broader adoption of Veeva Basics could also create opportunities to deepen customer relationships as these companies expand their technology needs, although the announcement did not quantify the expected revenue contribution from the offering.

Industry Prospects Favoring the MarketPer a report by Grand View Research, the global healthcare CRM market size was valued at $21.5 billion in 2025 and is projected to grow from $23.3 billion in 2026 to $35.7 billion by 2033, at a CAGR of 6.2% from 2026 to 2033.

The rising demand for structured data and automation in healthcare organizations is expected to drive market growth.  

Other NewsVEEV continues to strengthen its position in the life sciences software market as the Veeva DQS platform expands reach across clinical trials. The company said that the solution has now supported data cleaning across more than 1,000 studies involving over 1 million subjects, highlighting growing adoption of its clinical data management capabilities.

The expanding scale of Veeva DQS is encouraging as biopharma companies increasingly prioritize efficient data management amid rising clinical trial complexity.

VEEV’s Zacks Rank & Key PicksCurrently, VEEV has a Zacks Rank #3 (Hold).

Some better-ranked stocks from the broader medical space are Globus Medical (GMED - Free Report) , Veracyte (VCYT - Free Report) and West Pharmaceutical (WST - Free Report) .

Globus Medical, currently sporting a Zacks Rank #1 (Strong Buy), reported a second-quarter 2026 adjusted earnings per share (EPS) of $1.34, which surpassed the Zacks Consensus Estimate by 19.6%. Revenues of $789.6 million beat the Zacks Consensus Estimate by 0.4%. You can see the complete list of today’s Zacks #1 Rank stocks here.

GMED has an estimated long-term earnings growth rate of 12.4%. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 27.9%.

Veracyte, currently flaunting a Zacks Rank #1, reported a second-quarter 2026 adjusted EPS of 54 cents, which surpassed the Zacks Consensus Estimate by 25.6%. Revenues of $150.3 million beat the Zacks Consensus Estimate by 4.1%.

VCYT has an estimated earnings growth rate of 8.4% for 2026. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 41.8%.

West Pharmaceutical, carrying a Zacks Rank #2 (Buy) at present, reported second-quarter 2026 adjusted EPS of $2.37, which beat the Zacks Consensus Estimate by 13.9%. Revenues of $872.3 million surpassed the Zacks Consensus Estimate by 4.2%.

WST has an estimated long-term earnings growth rate of 16%. WST’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 17.4%.

Key Takeaways Veeva Systems' DQS has cleaned data for over 1 million subjects across more than 1,000 clinical studies.DQS generated over 500,000 automated queries, reducing manual effort in reconciling clinical trial data.AI, CTMS integration and Study Builder Agent expand DQS automation across clinical data workflows. Veeva Systems (VEEV - Free Report) continues to strengthen its position in the life sciences software market as its Veeva DQS (Data Quality System) platform expands its reach across clinical trials. The company said that the solution has now supported data cleaning across more than 1,000 studies involving over 1 million subjects, highlighting growing adoption of its clinical data management capabilities.

The expanding scale of Veeva DQS is encouraging as biopharma companies increasingly prioritize efficient data management amid rising clinical trial complexity. Broader adoption of the platform could support deeper customer engagement, reinforce Veeva’s position in clinical software and create additional opportunities for recurring revenue growth over the long term.

Likely Trend of VEEV Stock Following the NewsFollowing the announcement, shares of VEEV traded flat in yesterday’s market. Year to date, shares of the company have gained 27% compared with the industry’s 17.5% growth. However, the S&P 500 has risen 14.6% in the same timeframe.

Veeva DQS’ growing adoption could support Veeva’s long-term business by strengthening its footprint in clinical data management and increasing the value of its broader R&D platform. As sponsors and CROs manage larger volumes of complex clinical data, demand for automated and integrated data solutions is likely to rise.

Wider use of DQS can deepen Veeva’s relationships with existing customers, create cross-selling opportunities across its clinical applications and improve customer retention. Over time, this could contribute to more predictable recurring revenues while reinforcing Veeva’s competitive position in the life sciences software market.

VEEV currently has a market capitalization of $45.89 billion.

Image Source: Zacks Investment Research

Veeva DQS Expands Automation Across Clinical Data ManagementVeeva DQS has now aggregated and cleaned clinical trial data for more than 1 million subjects across more than 1,000 studies, underscoring the platform’s ability to operate at scale as clinical trials generate increasingly large and complex datasets. The system has also generated more than 500,000 automated queries, helping sites and sponsors reduce the manual effort involved in reconciling trial data and accelerating the availability of analysis-ready information. Adoption by sponsors and CROs across studies of different sizes provides a tangible indication of the platform’s growing role in modern clinical data management.

A key growth opportunity for Veeva DQS lies in its ability to connect clinical data management more closely with broader trial operations and emerging risk-based approaches. The platform supports automated data exchange with Veeva CTMS, enabling teams to identify changes such as protocol deviations and track key risk indicators as part of risk-based quality management.

DQS also incorporates AI to classify study data based on its purpose and criticality, potentially reducing repetitive work for clinical data teams. In addition, Veeva’s recently introduced Study Builder Agent is designed to configure Veeva EDC and DQS directly from study protocols, further connecting study setup with downstream data management. Together, these developments could increase the strategic importance of DQS within Veeva’s clinical platform and strengthen customer reliance on its integrated suite of applications.

Industry Prospects Favoring the MarketPer a report by Grand View Research, the global healthcare CRM market size was valued at $21.5 billion in 2025 and is projected to grow from $23.3 billion in 2026 to $35.7 billion by 2033, at a CAGR of 6.2% from 2026 to 2033.

The rising demand for structured data and automation in healthcare organizations is expected to drive market growth.  

Other NewsRecently, Veeva announced that Servier has selected Veeva OpenData to standardize customer reference data across more than 80 countries. The move strengthens Veeva’s position as a key provider of data solutions for global life sciences companies.

The deal underscores growing demand for high-quality, connected data as pharmaceutical companies look to scale artificial intelligence and advanced analytics.

VEEV’s Zacks Rank & Key PicksCurrently, VEEV has a Zacks Rank #3 (Hold).

Some better-ranked stocks from the broader medical space are Globus Medical (GMED - Free Report) , Veracyte (VCYT - Free Report) and West Pharmaceutical (WST - Free Report) .

Globus Medical, currently carrying a Zacks Rank #1 (Strong Buy), reported a second-quarter 2026 adjusted earnings per share (EPS) of $1.34, which surpassed the Zacks Consensus Estimate by 19.6%. Revenues of $789.6 million beat the Zacks Consensus Estimate by 0.4%. You can see the complete list of today’s Zacks #1 Rank stocks here.

GMED has an estimated long-term earnings growth rate of 12.4%. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 27.9%.

Veracyte, currently flaunting a Zacks Rank #1, reported a second-quarter 2026 adjusted EPS of 54 cents, which surpassed the Zacks Consensus Estimate by 25.6%. Revenues of $150.3 million beat the Zacks Consensus Estimate by 4.1%.

VCYT has an estimated earnings growth rate of 8.4% for 2026. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 41.8%.

West Pharmaceutical, carrying a Zacks Rank #2 (Buy) at present, reported second-quarter 2026 adjusted EPS of $2.37, which beat the Zacks Consensus Estimate by 13.9%. Revenues of $872.3 million surpassed the Zacks Consensus Estimate by 4.2%.

WST has an estimated long-term earnings growth rate of 16%. WST’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 17.4%.

Rockland Trust Co. lowered its position in Veeva Systems Inc. (NYSE:VEEV – Free Report) by 2.3% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 169,806 shares of the technology company’s stock after selling 3,954 shares during the quarter. Veeva Systems makes up about 1.9% of Rockland Trust Co.’s investment portfolio, making the stock its 12th largest holding. Rockland Trust Co. owned 0.10% of Veeva Systems worth $48,471,000 at the end of the most recent reporting period.

Other institutional investors also recently modified their holdings of the company. MassMutual Private Wealth & Trust FSB increased its position in Veeva Systems by 63.1% during the third quarter. MassMutual Private Wealth & Trust FSB now owns 938 shares of the technology company’s stock worth $268,000 after buying an additional 363 shares during the last quarter. CX Institutional lifted its position in shares of Veeva Systems by 72.3% in the third quarter. CX Institutional now owns 2,254 shares of the technology company’s stock valued at $643,000 after buying an additional 946 shares during the last quarter. Versant Capital Management Inc lifted its position in shares of Veeva Systems by 57.5% in the third quarter. Versant Capital Management Inc now owns 690 shares of the technology company’s stock valued at $197,000 after buying an additional 252 shares during the last quarter. Burkett Financial Services LLC bought a new position in shares of Veeva Systems during the 3rd quarter worth approximately $27,000. Finally, QRG Capital Management Inc. increased its holdings in shares of Veeva Systems by 8.6% during the 2nd quarter. QRG Capital Management Inc. now owns 16,280 shares of the technology company’s stock worth $2,889,000 after acquiring an additional 1,284 shares during the last quarter. 88.20% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets In related news, insider Thomas D. Schwenger sold 36,000 shares of the company’s stock in a transaction dated Thursday, August 13th. The shares were sold at an average price of $250.23, for a total transaction of $9,008,280.00. Following the completion of the sale, the insider owned 19,449 shares of the company’s stock, valued at $4,866,723.27. This represents a 64.92% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Priscilla Hung sold 750 shares of the stock in a transaction dated Wednesday, September 9th. The stock was sold at an average price of $261.04, for a total transaction of $195,780.00. Following the sale, the director owned 3,242 shares in the company, valued at $846,291.68. The trade was a 18.79% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 46,750 shares of company stock worth $12,017,360 in the last 90 days. 10.60% of the stock is owned by company insiders.

Veeva Systems Stock Performance Shares of NYSE VEEV traded up $3.71 during midday trading on Monday, reaching $277.04. The company’s stock had a trading volume of 441,643 shares, compared to its average volume of 2,357,317. The company has a market cap of $44.85 billion, a P/E ratio of 45.56, a P/E/G ratio of 1.17 and a beta of 0.93. The business’s 50 day moving average price is $252.60 and its two-hundred day moving average price is $200.16. Veeva Systems Inc. has a fifty-two week low of $148.05 and a fifty-two week high of $310.50. Veeva Systems (NYSE:VEEV – Get Free Report) last posted its quarterly earnings data on Wednesday, August 26th. The technology company reported $2.35 EPS for the quarter, topping analysts’ consensus estimates of $2.23 by $0.12. The firm had revenue of $927.96 million for the quarter, compared to analyst estimates of $905.38 million. Veeva Systems had a return on equity of 14.25% and a net margin of 29.34%.The company’s revenue was up 17.6% on a year-over-year basis. During the same quarter last year, the company earned $1.99 EPS. Veeva Systems has set its FY 2027 guidance at 9.210-9.210 EPS and its Q3 2027 guidance at 2.330-2.340 EPS. Sell-side analysts forecast that Veeva Systems Inc. will post 6.7 earnings per share for the current fiscal year.

Analyst Ratings Changes A number of research firms recently weighed in on VEEV. Jefferies Financial Group restated a “buy” rating and issued a $295.00 price target on shares of Veeva Systems in a research note on Thursday, August 27th. Canaccord Genuity Group upped their price objective on shares of Veeva Systems from $220.00 to $260.00 and gave the company a “hold” rating in a report on Thursday, August 27th. Wells Fargo & Company reissued an “overweight” rating and issued a $330.00 price objective on shares of Veeva Systems in a research report on Tuesday, September 8th. Mizuho raised their target price on shares of Veeva Systems from $270.00 to $280.00 and gave the stock an “outperform” rating in a research note on Thursday, August 27th. Finally, TD Cowen lifted their target price on shares of Veeva Systems from $235.00 to $283.00 and gave the stock a “buy” rating in a report on Monday, August 24th. Nineteen investment analysts have rated the stock with a Buy rating, eight have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $284.88.

View Our Latest Research Report on VEEV

Veeva Systems Profile (Free Report)

Veeva Systems Inc is a cloud software company that provides applications and services for the life sciences industry. Its customers include pharmaceutical, biotechnology, medical device and other organizations involved in developing, manufacturing and commercializing regulated products.

The company’s product portfolio includes the Veeva Vault platform, which supports areas such as clinical operations, regulatory affairs, quality management, safety and medical communications. Veeva also offers commercial and customer relationship management applications, data and analytics products, and services designed to help life sciences companies manage relationships with healthcare professionals, oversee content and improve operational efficiency.

Founded in 2007, Veeva serves customers globally and has expanded its offerings from commercial software into research, development, manufacturing and quality processes.

Read More Five stocks we like better than Veeva Systems A Manufacturing Surprise Could Be a Big Win for These 2 Companies What a $1 Billion Chip Deal Says About Amazon’s AI Ambitions 3 Stocks Benefiting From AI Demand Just Announced Major Buybacks Insiders Are Selling These 3 Stocks, Should You?

Receive News & Ratings for Veeva Systems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Veeva Systems and related companies with MarketBeat.com's FREE daily email newsletter.

A month has gone by since the last earnings report for Veeva Systems (VEEV - Free Report) . Shares have lost about 2.6% in that time frame, underperforming the S&P 500.

Will the recent negative trend continue leading up to its next earnings release, or is Veeva due for a breakout? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the latest earnings report in order to get a better handle on the important catalysts.

Veeva Systems Q2 Earnings and Revenues Beat EstimatesVeeva Systems reported adjusted earnings per share of $2.35 for the second quarter of fiscal 2027, which increased 18.1% from the year-ago figure of $1.99. Adjusted earnings per share beat the Zacks Consensus Estimate by 5.9%.

GAAP earnings per share in the fiscal second quarter was $1.66, up 39.5% from the year-ago period’s $1.37.

VEEV’s second-quarter revenues rose 17.6% to $928 million and topped the consensus estimate by 2.7%. Growth reflected strength across subscriptions and services, while Vault CRM ended the quarter with more than 180 customers live.

VEEV’s Q2 Segmental DetailsThe fiscal second-quarter revenue growth was driven by strength across Subscription services and Professional services and other revenues.

Subscription services revenues increased 16.3% year over year to $766.8 million.

Professional services and other revenues advanced 24.1% year over year to $161.2 million.

Q2 Margin Performance by VEEVIn the quarter under review, Veeva Systems’ gross profit increased 17.2% year over year to $695.9 million. However, the gross margin contracted 30 basis points (bps) to 75%.

Sales and marketing expenses increased 15.8% year over year to $126.7 million. Research and development expenses rose 15.7% year over year to $222.9 million, while general and administrative expenses declined 25.6% year over year to $71.3 million. Total operating expenses of $420.9 million increased 5.8% year over year.

Operating profit totaled $275 million, up 40.4% from the prior-year quarter. The operating margin in the fiscal second quarter expanded 480 bps to 29.6%.

VEEV’s Financial PositionThe company exited second-quarter fiscal 2027 with cash and cash equivalents and short-term investments of $7.24 billion compared with $7.31 billion at the fiscal first quarter of 2027-end.

Cumulative net cash provided by operating activities at the end of the quarter was $1.37 billion compared with $1.12 billion a year ago.

Q3 & FY27 Guidance Provided by VEEVVeeva Systems has issued its financial outlook for the fiscal third quarter and raised its guidance for fiscal 2027.

For the fiscal third quarter, the company expects total revenues in the range of $932-$935 million. Subscription revenues are projected to be approximately $782 million, while Professional services and other revenues are anticipated between $150 million and $153 million.

Adjusted earnings per share is projected between $2.33 and $2.34.

For fiscal 2027, Veeva Systems now expects revenues between $3.682 billion and $3.687 billion. Subscription revenues are projected to be approximately $3.08 billion, comprising Commercial Solutions subscription revenues of around $1.405 billion and R&D and Quality Solutions subscription revenues of approximately $1.675 billion. Professional services and other revenues are expected in the range of $602-$607 million.

Adjusted earnings per share is now expected to be approximately $9.21.

How Have Estimates Been Moving Since Then?Since the earnings release, investors have witnessed a upward trend in estimates review.

VGM ScoresCurrently, Veeva has a nice Growth Score of B, though it is lagging a lot on the Momentum Score front with a D. Following the exact same course, the stock was allocated a score of D on the value side, putting it in the bottom 40% for value investors.

Overall, the stock has an aggregate VGM Score of C. If you aren't focused on one strategy, this score is the one you should be interested in.

OutlookEstimates have been trending upward for the stock, and the magnitude of these revisions looks promising. Notably, Veeva has a Zacks Rank #3 (Hold). We expect an in-line return from the stock in the next few months.

Key Takeaways Veeva's Falcon Router automates intake and routing of safety, quality and medical cases.Early adopter availability is set for January 2027, with email and web intake in the initial rollout.Veeva's Falcon Router can reduce manual workloads and improve compliance workflows across Vault. Veeva Systems (VEEV - Free Report) recently expanded its AI strategy with the launch of Falcon Router, a new agentic solution designed to help biopharma companies streamline the intake and routing of safety, quality and medical cases across reporting channels. The offering, scheduled for early adopter availability in January 2027, adds to Veeva's growing Falcon Agent Suite aimed at automating industry-specific workflows.

The launch reinforces Veeva's push to deepen its footprint in life sciences through AI-driven workflow automation rather than standalone generative AI tools. By embedding agentic capabilities into regulated business processes, the company could strengthen adoption across its Vault ecosystem, expand cross-selling opportunities and support long-term recurring revenue growth as pharmaceutical customers increasingly invest in operational efficiency.

Likely Trend of VEEV Stock Following the NewsFollowing the announcement, shares of VEEV traded flat in yesterday’s trading. Year to date, shares of the company have ganied 16.8% compared with the industry’s 14.5% growth. However, the S&P 500 has risen 13.1% in the same timeframe.

In the long term, Falcon Router could strengthen Veeva's competitive position by making its Vault ecosystem more integral to biopharma companies' daily operations. By automating the triage and routing of safety, quality and medical inquiries into Veeva Safety, QMS and MedInquiry, the solution can reduce manual workloads and improve compliance workflows.

As life sciences companies expand across products and geographies, this deeper workflow integration could drive broader adoption of Veeva's AI-powered applications, support cross-selling opportunities across the Falcon Agent Suite and reinforce the company's recurring subscription revenue growth over time.

VEEV currently has a market capitalization of $42.31 billion.

Image Source: Zacks Investment Research

More on the NewsVeeva's newest Falcon Router addresses a persistent operational challenge for biopharma companies by automatically identifying and routing incoming safety adverse event reports, product quality complaints and medical inquiries to the appropriate internal teams. Instead of relying on manual sorting and reconciliation across multiple reporting channels, the AI-powered agent orchestrates these triage decisions automatically, helping organizations process high-priority cases with greater speed and consistency.

The initial rollout focuses on email and web-based intake channels, including Veeva Ostro, allowing organizations to capture information from commonly used customer communication touchpoints. Once a case is classified, Falcon Router directs it to the appropriate destination, including Veeva Safety, Veeva QMS, Veeva MedInquiry or designated inboxes, reducing delays that often occur when cases require manual reassignment between departments.

Management believes that the solution becomes increasingly valuable as pharmaceutical companies expand into new products, therapeutic areas and global markets, where reporting volumes and regulatory obligations become more complex. Early adopter availability is scheduled for January 2027, positioning Falcon Router as the latest addition to Veeva's Falcon Agent Suite, which is designed to bring industry-specific agentic automation to regulated life sciences workflows.

The Three Core Products Supporting Falcon RouterVeeva Safety

Veeva Safety is the company's cloud-based pharmacovigilance platform that helps life sciences companies capture, process and report adverse events throughout a product's lifecycle. The platform supports regulatory compliance by managing safety cases, automating reporting workflows and maintaining comprehensive records required by health authorities. By integrating Falcon Router directly into Veeva Safety, incoming adverse event reports can be classified and transferred into established safety workflows more efficiently, enabling pharmacovigilance teams to focus on case evaluation rather than manual intake management.

Veeva QMS

Veeva QMS serves as Veeva's quality management system for regulated manufacturing and quality operations. The platform helps pharmaceutical and biotechnology companies manage quality events, deviations, corrective and preventive actions, change controls, audits and training within a unified cloud environment. Falcon Router strengthens this workflow by automatically directing product quality complaints into QMS, helping quality teams initiate investigations sooner while maintaining documented processes that support regulatory compliance and operational consistency across manufacturing operations.

Veeva MedInquiry

Veeva MedInquiry is part of Veeva Vault Medical and is designed to manage medical information requests from healthcare professionals, patients and other stakeholders. The application enables medical affairs teams to capture inquiries, deliver approved scientific responses and maintain compliant documentation of every interaction. Through Falcon Router, medical inquiries submitted through email or web channels can be automatically identified and routed into MedInquiry, helping organizations deliver faster responses while ensuring inquiries reach the appropriate medical experts without unnecessary manual intervention.

Industry Prospects Favoring the MarketPer a report by Grand View Research, the global healthcare CRM market size was valued at $21.5 billion in 2025 and is projected to grow from $23.3 billion in 2026 to $35.7 billion by 2033, at a CAGR of 6.2% from 2026 to 2033.

The rising demand for structured data and automation in healthcare organizations is expected to drive market growth.  

Other NewsRecently, Veeva exited the second quarter of fiscal 2027 with better-than-expected results, wherein both earnings and revenues beat the Zacks Consensus Estimate. The company also raised its fiscal 2027 outlook. Strong execution across Commercial Solutions and R&D and Quality Solutions, along with continued momentum in newer growth areas, remained encouraging.

VEEV’s Zacks Rank & Key PicksCurrently, VEEV has a Zacks Rank #3 (Hold).

Some better-ranked stocks from the broader medical space are Globus Medical (GMED - Free Report) , Veracyte (VCYT - Free Report) and West Pharmaceutical (WST - Free Report) .

Globus Medical, currently carrying a Zacks Rank #2 (Buy), reported a second-quarter 2026 adjusted earnings per share (EPS) of $1.34, which surpassed the Zacks Consensus Estimate by 19.6%. Revenues of $789.6 million beat the Zacks Consensus Estimate by 0.4%. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

GMED has an estimated long-term earnings growth rate of 12.4%. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 27.9%.

Veracyte, currently flaunting a Zacks Rank #1, reported a second-quarter 2026 adjusted EPS of 54 cents, which surpassed the Zacks Consensus Estimate by 25.6%. Revenues of $150.3 million beat the Zacks Consensus Estimate by 4.1%.

VCYT has an estimated earnings growth rate of 8.4% for 2026. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 41.8%.

West Pharmaceutical, carrying a Zacks Rank #2 at present, reported second-quarter 2026 adjusted EPS of $2.37, which beat the Zacks Consensus Estimate by 13.9%. Revenues of $872.3 million surpassed the Zacks Consensus Estimate by 4.2%.

WST has an estimated long-term earnings growth rate of 16%. WST’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 17.4%.

Key Takeaways Amgen selected Veeva Vault CRM for global deployment, extending a partnership of more than a decade.Veeva's Vault CRM has 180 live customers and expects to retain more than 70% CRM market share.Commercial subscription revenue rose about 13% year over year on broad-based CRM, data and Crossix strength. Veeva Systems (VEEV - Free Report) recently announced that Amgen (AMGN - Free Report) has selected its Vault CRM for a global deployment, extending a collaboration that has spanned more than a decade. The rollout is expected to support Amgen's commercial operations as it advances new therapies across worldwide markets.

The deal reinforces Veeva's strengthening commercial business, where management recently highlighted the best CRM quarter ever and continued enterprise adoption of Vault CRM during its latest earnings call. The Amgen win also adds momentum to Veeva's strategy of deepening relationships with large biopharma customers, an important driver of long-term subscription growth.

Likely Trend of VEEV Stock Following the NewsFollowing the announcement, shares of VEEV traded flat in yesterday’s trading. Year to date, shares of the company have gained 16.8% compared with the industry’s 13.5% growth. However, the S&P 500 has risen 11.4% in the same timeframe.

Amgen's global adoption of Vault CRM strengthens Veeva's long-term commercial growth strategy by reinforcing its position as the preferred CRM partner for large biopharma companies. The win comes as management recently highlighted its strongest-ever CRM quarter, more than 180 live Vault CRM customers and growing confidence in retaining more than 70% market share in the CRM space.

Beyond expanding recurring subscription revenue, the deployment could create additional cross-sell opportunities across Veeva's broader commercial suite as global customers increasingly seek integrated, AI-enabled platforms for commercial operations.

VEEV currently has a market capitalization of $42.13 billion.

Image Source: Zacks Investment Research

More on the NewsAmgen's decision to standardize on Veeva Vault CRM globally marks another major enterprise validation for the company's next-generation commercial platform, extending a partnership that has lasted for more than a decade. Amgen said that the migration will help accelerate the delivery of new therapies worldwide with greater speed and agility, while Veeva noted that the platform will serve as the commercial foundation for launching innovative medicines across global markets.

The latest deployment further demonstrates how leading pharmaceutical and biotechnology companies are increasingly turning to Vault CRM as they modernize commercial operations on a unified, life sciences-focused platform.

Vault CRM's expanding adoption is being driven by its AI-enabled commercial capabilities that help life sciences companies improve engagement with healthcare professionals. As part of the broader Vault CRM Suite, the platform supports an agentic commercial model that combines commercial workflows with AI-powered capabilities such as Agentic Call Report, which generates commercial evidence and helps uncover previously hidden treatment barriers.

These features enable field teams to streamline customer interactions while providing commercial organizations with deeper insights, making the platform increasingly attractive for large pharmaceutical and biotech companies seeking integrated commercial solutions instead of fragmented legacy systems.

The Amgen win also aligns with the strong commercial momentum highlighted during Veeva's latest earnings call. Management described fiscal second-quarter 2027 as its best CRM quarter ever, with commercial subscription revenue growing about 13% year over year on broad-based strength across CRM, content, data and Crossix.

Veeva also emphasized that Vault CRM now has more than 180 live customers, including large enterprise deployments, while management reiterated confidence in maintaining more than 70% market share in life sciences CRM as customers increasingly prioritize proven, AI-enabled commercial platforms.

Industry Prospects Favoring the MarketPer a report by Grand View Research, the global healthcare CRM market size was valued at $21.5 billion in 2025 and is projected to grow from $23.3 billion in 2026 to $35.7 billion by 2033, at a CAGR of 6.2% from 2026 to 2033.

The rising demand for structured data and automation in healthcare organizations is expected to drive market growth.  

Other NewsRecently, Veeva exited the second quarter of fiscal 2027 with better-than-expected results, wherein both earnings and revenues beat the Zacks Consensus Estimate. The company also raised its fiscal 2027 outlook. Strong execution across Commercial Solutions and R&D and Quality Solutions, along with continued momentum in newer growth areas, remained encouraging.

VEEV’s Zacks Rank & Key PicksCurrently, VEEV has a Zacks Rank #3 (Hold).

Some better-ranked stocks from the broader medical space are Globus Medical (GMED - Free Report) and Veracyte (VCYT - Free Report) .

Globus Medical, currently carrying a Zacks Rank #2 (Buy), reported a second-quarter 2026 adjusted earnings per share (EPS) of $1.34, which surpassed the Zacks Consensus Estimate by 19.6%. Revenues of $789.6 million beat the Zacks Consensus Estimate by 0.4%. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

GMED has an estimated long-term earnings growth rate of 12.4%. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 27.9%.

Veracyte, currently flaunting a Zacks Rank #1, reported a second-quarter 2026 adjusted EPS of 54 cents, which surpassed the Zacks Consensus Estimate by 25.6%. Revenues of $150.3 million beat the Zacks Consensus Estimate by 4.1%.

VCYT has an estimated earnings growth rate of 8.4% for 2026. The company’s earnings beat estimates in each of the trailing four quarters, with the average surprise being 41.8%.

Base de CRM de agentes para ayudar a acelerar la entrega de medicamentos innovadores a pacientes de todo el mundo.

, /PRNewswire/ -- Veeva Systems (NYSE: VEEV) anunció hoy que Amgen planea implementar Veeva Vault CRM  a nivel mundial, consolidando una colaboración que abarca más de una década.

"Migrar a Vault CRM ayudará a acelerar nuestros esfuerzos por llevar nuevas terapias a pacientes de todo el mundo con mayor rapidez y agilidad", afirmó Scott Skellenger, vicepresidente sénior y director de información de Amgen. "El profundo conocimiento de Veeva sobre el sector de las ciencias de la vida, su enfoque continuo en la innovación y nuestra colaboración de larga trayectoria contribuirán a que Amgen alcance estos importantes objetivos".

"Vault CRM proporcionará la base comercial impulsada por agentes para ayudar a Amgen a llevar medicamentos innovadores —destinados a algunas de las enfermedades más difíciles del mundo— a millones de pacientes", afirmó Matt Farrell, presidente de estrategia comercial de Veeva. "Esperamos apoyar a Amgen en el lanzamiento de nuevas e importantes terapias a nivel mundial".

Vault CRM forma parte de Vault CRM Suite, la base tecnológica para la actividad comercial basada en agentes, la cual transforma la manera en que el sector interactúa con los profesionales sanitarios (HCP) para acelerar los resultados de los lanzamientos y mejorar los desenlaces de los pacientes. Incluye la función Agentic Call Report para generar evidencia comercial y detectar barreras de tratamiento que antes pasaban inadvertidas.

Acerca de Veeva Systems
Veeva ofrece la nube sectorial para las ciencias de la vida, que incluye aplicaciones, agentes, datos y servicios de consultoría. Con un firme compromiso hacia la innovación, la excelencia del producto y el éxito del cliente, Veeva atiende a más de 1.500 clientes, desde las mayores empresas farmacéuticas del mundo hasta compañías biotecnológicas emergentes. Como empresa de beneficio público (Public Benefit Corporation), Veeva se compromete a equilibrar los intereses de todas las partes interesadas, incluidos clientes, empleados, accionistas y los sectores a los que presta servicio. Para obtener más información, visite veeva.com.

Declaraciones prospectivas de Veeva
Este comunicado contiene declaraciones prospectivas relativas a los productos y servicios de Veeva y a los resultados o beneficios previstos derivados de su uso. Dichas declaraciones se basan en nuestras expectativas actuales. Los resultados reales podrían diferir sustancialmente de los indicados en este comunicado, y no asumimos obligación alguna de actualizar tales declaraciones. Existen numerosos riesgos que podrían afectar negativamente a nuestros resultados, incluidos los riesgos e incertidumbres detallados en nuestra presentación del Formulario 10-Q correspondiente al ejercicio fiscal finalizado el 31 de julio de 2026, disponible aquí (encontrará un resumen de los riesgos que pueden afectar a nuestro negocio en las páginas 33 y 34), y en nuestras presentaciones posteriores ante la SEC, a las que puede acceder en sec.gov.

Brown Lisle Cummings Inc. reduced its stake in Veeva Systems Inc. (NYSE:VEEV – Free Report) by 58.1% during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 7,293 shares of the technology company’s stock after selling 10,120 shares during the quarter. Brown Lisle Cummings Inc.’s holdings in Veeva Systems were worth $1,294,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors also recently made changes to their positions in the stock. California State Teachers Retirement System increased its holdings in shares of Veeva Systems by 16,590.3% during the second quarter. California State Teachers Retirement System now owns 39,388,224 shares of the technology company’s stock valued at $6,990,228,000 after acquiring an additional 39,152,230 shares in the last quarter. Principal Financial Group Inc. boosted its stake in Veeva Systems by 7.0% in the 1st quarter. Principal Financial Group Inc. now owns 4,141,545 shares of the technology company’s stock worth $727,513,000 after purchasing an additional 271,252 shares in the last quarter. State Street Corp grew its position in Veeva Systems by 2.4% during the 4th quarter. State Street Corp now owns 3,589,425 shares of the technology company’s stock valued at $801,267,000 after purchasing an additional 85,695 shares during the last quarter. Geode Capital Management LLC increased its stake in Veeva Systems by 0.7% during the 4th quarter. Geode Capital Management LLC now owns 3,172,716 shares of the technology company’s stock valued at $706,442,000 after purchasing an additional 23,117 shares in the last quarter. Finally, AQR Capital Management LLC increased its stake in Veeva Systems by 31.2% during the 3rd quarter. AQR Capital Management LLC now owns 2,412,210 shares of the technology company’s stock valued at $706,078,000 after purchasing an additional 574,164 shares in the last quarter. Hedge funds and other institutional investors own 88.20% of the company’s stock.

Analyst Upgrades and Downgrades VEEV has been the subject of several recent analyst reports. Jefferies Financial Group reaffirmed a “buy” rating and issued a $295.00 target price on shares of Veeva Systems in a report on Thursday, August 27th. Canaccord Genuity Group boosted their price objective on shares of Veeva Systems from $220.00 to $260.00 and gave the stock a “hold” rating in a report on Thursday, August 27th. Royal Bank Of Canada upped their price objective on Veeva Systems from $275.00 to $325.00 and gave the company an “outperform” rating in a research report on Thursday, August 27th. The Goldman Sachs Group cut their target price on Veeva Systems from $190.00 to $165.00 and set a “sell” rating on the stock in a research note on Thursday, June 4th. Finally, Truist Financial lifted their target price on Veeva Systems from $262.00 to $305.00 and gave the stock a “buy” rating in a report on Thursday, August 27th. Nineteen research analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, Veeva Systems presently has an average rating of “Moderate Buy” and a consensus price target of $284.46.

Read Our Latest Analysis on VEEV Veeva Systems Stock Down 0.4% Shares of VEEV stock opened at $274.02 on Tuesday. The company has a 50 day moving average price of $222.45 and a 200-day moving average price of $188.73. Veeva Systems Inc. has a 52 week low of $148.05 and a 52 week high of $310.50. The firm has a market capitalization of $44.37 billion, a PE ratio of 45.07, a P/E/G ratio of 1.17 and a beta of 0.97.

Veeva Systems (NYSE:VEEV – Get Free Report) last issued its quarterly earnings data on Wednesday, August 26th. The technology company reported $2.35 earnings per share for the quarter, beating analysts’ consensus estimates of $2.23 by $0.12. Veeva Systems had a net margin of 29.34% and a return on equity of 14.25%. The company had revenue of $927.96 million for the quarter, compared to the consensus estimate of $905.38 million. During the same quarter in the prior year, the firm earned $1.99 earnings per share. The firm’s revenue for the quarter was up 17.6% compared to the same quarter last year. Veeva Systems has set its FY 2027 guidance at 9.210-9.210 EPS and its Q3 2027 guidance at 2.330-2.340 EPS. Analysts anticipate that Veeva Systems Inc. will post 6.7 earnings per share for the current year.

Insiders Place Their Bets In other news, insider Thomas Schwenger sold 10,000 shares of the stock in a transaction on Thursday, August 27th. The stock was sold at an average price of $281.33, for a total transaction of $2,813,300.00. Following the transaction, the insider directly owned 19,449 shares of the company’s stock, valued at $5,471,587.17. This represents a 33.96% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 10.60% of the company’s stock.

Veeva Systems Company Profile (Free Report)

Veeva Systems (NYSE: VEEV) is a cloud software company that develops industry-specific applications and data solutions for the global life sciences sector. Founded in 2007 and headquartered in Pleasanton, California, Veeva focuses on helping pharmaceutical, biotechnology, medical device and consumer health companies manage regulated content, clinical and regulatory processes, quality systems, and commercial operations in a compliant, cloud-native environment. The company completed its initial public offering in 2013 and has since expanded its product suite and international footprint.

Veeva’s product portfolio centers on its Vault platform and related application suites, which provide content and data management, clinical trial and regulatory workflows, quality management, and structured commercial capabilities such as customer relationship management and promotional content management.

Recommended Stories Five stocks we like better than Veeva Systems 3 Under-the-Radar Defense Stocks With Record Backlogs This Korea ETF Has Soared, But the Rally May Not Be Over Why Guidewire’s Post-Earnings Plunge May Not Last Ride-Share Reckoning: Tesla Drives Into Uber’s Lane Want to see what other hedge funds are holding VEEV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Veeva Systems Inc. (NYSE:VEEV – Free Report).

Receive News & Ratings for Veeva Systems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Veeva Systems and related companies with MarketBeat.com's FREE daily email newsletter.

Michael Burry Takes Profits in Veeva. But He Has a Stark Warning for Snowflake Summary

Michael Burry trimmed his Veeva position after the shares rallied sharply while maintaining a bullish view on the software company

Michael Burry (Trades, Portfolio) has kept a bullish stance on Veeva Systems VEEV while reducing part of his holding after a rapid increase in the shares.

Burry disclosed the position earlier this year as part of a broader view that software stocks could recover. He later added to the investment before trimming it as Veeva approached a level he considered a potential barrier for further gains.

The move does not signal that Burry has abandoned the company. His comments indicate that valuation and the speed of the rally influenced the decision to reduce exposure rather than exit the investment.

Burry also raised concerns about Snowflake SNOW, describing its valuation as difficult to justify and pointing to potential long-term risks from cybersecurity developments involving artificial general intelligence and quantum computing.

Snowflake's shares, however, rose more than 23% in premarket trading after its latest results exceeded expectations. The company lifted its fiscal 2027 product-revenue forecast to $6.07 billion, representing 36% annual growth, from $5.84 billion previously.

Burry's Veeva trim may temper sentiment, while Snowflake's stronger outlook could offset valuation concerns.

Also check out:

Michael Burry Undervalued Stocks Michael Burry Top Growth Companies Michael Burry High Yield stocks, and Stocks that Michael Burry keeps buying Disclosures I/we have no positions in any stocks mentioned, and have no plans to buy any new positions in the stocks mentioned within the next 72 hours.

Click for the complete disclosure

Total Revenues of $928.0M, up 18% Year Over Year
Subscription Revenues of $766.8M, up 16% Year Over Year

, /PRNewswire/ -- Veeva Systems Inc. (NYSE: VEEV), a leading provider of industry cloud solutions for the global life sciences industry, today announced results for its second quarter ended July 31, 2026.

"AI is opening up the next big chapter for Veeva and life sciences," said CEO Peter Gassner. "Vault CRM had its best quarter ever and Veeva Falcon accelerated rapidly. By bringing together deep industry applications, agents, data, and consulting, we are helping the industry drive new efficiencies from clinical to commercial and deliver better outcomes for patients."

Fiscal 2027 Second Quarter Results:

Revenues: Total revenues for the second quarter were $928.0 million, up from $789.1 million one year ago, an increase of 18% year over year. Subscription revenues for the second quarter were $766.8 million, up from $659.2 million one year ago, an increase of 16% year over year. Operating Income and Non-GAAP Operating Income:(1) Second quarter operating income was $275.0 million, compared to $195.9 million one year ago, an increase of 40% year over year. Non-GAAP operating income for the second quarter was $415.9 million, compared to $352.6 million one year ago, an increase of 18% year over year. Net Income and Non-GAAP Net Income:(1) Second quarter net income was $273.4 million, compared to $200.3 million one year ago, an increase of 37% year over year. Non-GAAP net income for the second quarter was $387.4 million, compared to $333.4 million one year ago, an increase of 16% year over year. Net Income per Share and Non-GAAP Net Income per Share:(1) For the second quarter, fully diluted net income per share was $1.66, compared to $1.19 one year ago, while non-GAAP fully diluted net income per share was $2.35, compared to $1.99 one year ago. "Second quarter results exceeded guidance on all metrics and our view for the full year improved across the board," said CFO Brian Van Wagener. "We continue to execute well across the business while also accelerating innovation and progress in new growth areas."

Recent Highlights:

Vault CRM Leadership Grows with More Top 20 Wins, Go-lives, and AI Adoption – Vault CRM leadership grew with more than 180 customers live, including five top 20 biopharmas. In August, two top 20 biopharmas and one large enterprise biopharma committed to Vault CRM, bringing total top 20 commitments to 12 globally. As the industry's fastest path to agentic CRM, a top 20 biopharma deployed Vault CRM and the Agentic Call Report across its full U.S. field team in the quarter. Major AI Milestones for Vault AI and Falcon, and Agentic MLR Launches – Veeva AI advanced rapidly across all areas. Development of Veeva Falcon, the agentic labor platform for clinical, regulatory, and safety, is moving quickly with five early adopters and on track for initial go-lives this year. The company also acquired Copli in the quarter and launched Veeva Falcon MLR to automate content reviews. August marked a major milestone for Vault AI with new standard agents, broader capabilities for existing agents, and advanced tools for custom agent development. Delivering the Connected Foundation for R&D and Quality – Development Cloud and Quality Cloud saw broad adoption, deepening relationships with new and existing customers. In clinical, a large enterprise biopharma selected Veeva EDC, building on its existing eTMF, CTMS, and Study Startup foundation. Veeva Safety surpassed 100 total customers while securing its second top 20 biopharma win for Safety Workbench. In Quality, Veeva added more than 30 new customers, driven by 20 or more wins each across QualityDocs, QMS, and Training. Financial Outlook:

Veeva is providing guidance for its fiscal third quarter ending October 31, 2026 as follows:

Total revenues between $932 and $935 million. Non-GAAP operating income between $417 and $420 million.(2) Non-GAAP fully diluted net income per share between $2.33 and $2.34.(2) Veeva is providing updated guidance for its fiscal year ending January 31, 2027 as follows:

Total revenues between $3,682 and $3,687 million. Non-GAAP operating income of about $1,640 million.(2) Non-GAAP fully diluted net income per share of approximately $9.21.(2) Conference Call Information

Prepared remarks and an investor presentation providing additional information and analysis can be found on Veeva's investor relations website at ir.veeva.com. Veeva will host a Q&A conference call at 2:00 p.m. PT today, August 26, 2026, and a replay of the call will be available on Veeva's investor relations website.

(1) This press release uses non-GAAP financial metrics that are adjusted for the impact of various GAAP items. See the section titled "Non-GAAP Financial Measures" and the tables entitled "Reconciliation of GAAP to Non-GAAP Financial Measures" below for details.

(2) Veeva is not able, at this time, to provide GAAP targets for operating income and fully diluted net income per share for the third fiscal quarter ending October 31, 2026 or the fiscal year ending January 31, 2027 because of the difficulty of estimating certain items excluded from non-GAAP operating income and non-GAAP fully diluted net income per share that cannot be reasonably predicted, such as charges related to stock-based compensation expense. The effect of these excluded items may be significant.

About Veeva Systems

Veeva delivers the industry cloud for life sciences with applications, agents, data, and consulting. Committed to innovation, product excellence, and customer success, Veeva serves more than 1,500 customers, ranging from the world's largest pharmaceutical companies to emerging biotechs. As a Public Benefit Corporation, Veeva is committed to balancing the interests of all stakeholders, including customers, employees, shareholders and the industries it serves. For more information, visit veeva.com.

Veeva uses its ir.veeva.com website as a means of disclosing material non-public information, announcing upcoming investor conferences, and for complying with its disclosure obligations under Regulation FD. Accordingly, you should monitor our investor relations website in addition to following our press releases, SEC filings, and public conference calls and webcasts.

Forward-looking Statements

This release contains forward-looking statements regarding Veeva's expected future performance and, in particular, includes quotes from management and guidance, provided as of August 26, 2026, about Veeva's expected future financial results. Estimating guidance accurately for future periods is difficult. It involves assumptions and internal estimates that may prove to be incorrect and is based on plans that may change. Hence, there is a significant risk that actual results could differ materially from the guidance we have provided in this release and we have no obligation to update such guidance. There are also numerous risks that have the potential to negatively impact our financial performance, including issues related to the performance, availability, security, or privacy of our products, competitive factors, customer decisions and priorities, developments that impact the life sciences industry (including regulatory, funding, or policy changes), general macroeconomic and geopolitical events (including changes in trade policy or practices, inflationary pressures, currency exchange fluctuations, changes in interest rates, and geopolitical conflicts), and issues that impact our ability to hire, retain and adequately compensate talented employees. We have summarized what we believe are the principal risks to our business in a section titled "Summary of Risk Factors" on pages 33 and 34 in our filing on Form 10-Q for the period ended April 30, 2026 which you can find here. Additional details on the risks and uncertainties that may impact our business can be found in the same filing on Form 10-Q and in our subsequent SEC filings, which you can access at sec.gov. We recommend that you familiarize yourself with these risks and uncertainties before making an investment decision.

Investor Relations Contact:

Media Contact:

Gunnar Hansen

Maria Scurry

Veeva Systems Inc.

Veeva Systems Inc.

267-460-5839

781-366-7617

[email protected]

[email protected]

VEEVA SYSTEMS INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

(In thousands)

(Unaudited)

July 31,
2026

January 31,
2026

Assets

Current assets:

Cash and cash equivalents

$    1,812,012

$    1,421,233

Short-term investments

5,430,935

5,139,581

Accounts receivable, net

496,677

1,259,737

Unbilled accounts receivable

68,970

50,609

Prepaid expenses and other current assets

137,633

126,470

Total current assets

7,946,227

7,997,630

Property and equipment, net

79,483

70,261

Deferred costs, net

27,835

29,961

Lease right-of-use assets

129,320

75,626

Goodwill

492,991

439,877

Intangible assets, net

55,647

30,314

Deferred income taxes

268,250

273,417

Other long-term assets

60,470

62,257

Total assets

$    9,060,223

$    8,979,343

Liabilities and stockholders' equity

Current liabilities:

Accounts payable

$       35,977

$       37,644

Accrued compensation and benefits

42,188

45,857

Accrued expenses and other current liabilities

49,634

45,885

Income tax payable

3,018

6,698

Deferred revenue

1,310,498

1,488,819

Lease liabilities

14,635

12,153

Total current liabilities

1,455,950

1,637,056

Deferred income taxes

2,056

558

Long-term lease liabilities

137,060

83,706

Other long-term liabilities

33,708

43,271

Total liabilities

1,628,774

1,764,591

Stockholders' equity:

Common stock

2

2

Additional paid-in capital

2,579,728

2,843,089

Accumulated other comprehensive (loss) income

(46,147)

8,160

Retained earnings

4,897,866

4,363,501

Total stockholders' equity

7,431,449

7,214,752

Total liabilities and stockholders' equity

$    9,060,223

$    8,979,343

VEEVA SYSTEMS INC.

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME

(In thousands, except per share data)

(Unaudited)

Three months ended July 31,

Six months ended July 31,

2026

2025

2026

2025

Revenues:

Subscription(3)

$      766,764

$      659,183

$    1,496,939

$    1,293,951

Professional services and other(4)

161,199

129,898

313,972

254,173

Total revenues

927,963

789,081

1,810,911

1,548,124

Cost of revenues(5):

Cost of subscription

105,677

93,830

204,780

172,176

Cost of professional services and other

126,335

101,423

248,156

196,901

Total cost of revenues

232,012

195,253

452,936

369,077

Gross profit

695,951

593,828

1,357,975

1,179,047

Operating expenses(5):

Research and development

222,918

192,677

431,241

376,710

Sales and marketing

126,701

109,439

237,818

208,067

General and administrative

71,314

95,804

140,786

164,630

Total operating expenses

420,933

397,920

809,845

749,407

Operating income

275,018

195,908

548,130

429,640

Other income, net

74,512

69,456

148,930

134,545

Income before income taxes

349,530

265,364

697,060

564,185

Income tax provision

76,101

65,055

162,695

135,686

Net income

$      273,429

$      200,309

$      534,365

$      428,499

Net income per share:

Basic

$          1.68

$          1.23

$          3.28

$          2.63

Diluted

$          1.66

$          1.19

$          3.22

$          2.56

Weighted-average shares used to compute net income per share:

Basic

162,344

163,496

162,836

163,129

Diluted

165,057

167,685

166,072

167,272

Other comprehensive income:

Net change in unrealized (loss) gain on available-for-sale investments

$      (26,490)

$      (11,300)

$      (53,941)

$        6,067

Net change in cumulative foreign currency translation gain (loss)

135

390

(366)

352

Comprehensive income

$      247,074

$      189,399

$      480,058

$      434,918

(3) Includes subscription revenues from the following product areas:

Veeva Commercial Solutions

$      347,389

$      307,523

$      685,255

$      612,934

Veeva R&D and Quality Solutions

419,375

351,660

811,684

681,017

Total subscription

$      766,764

$      659,183

$    1,496,939

$    1,293,951

(4) Includes professional services and other revenues from the following product areas:

Veeva Commercial Solutions

$       59,742

$       47,703

$      117,315

$       94,270

Veeva R&D and Quality Solutions

101,457

82,195

196,657

159,903

Total professional services and other

$      161,199

$      129,898

$      313,972

$      254,173

(5) Includes stock-based compensation as follows:

Cost of revenues:

Cost of subscription

$        2,224

$        1,941

$        3,985

$        3,656

Cost of professional services and other

15,939

14,804

30,090

27,573

Research and development

62,220

53,388

113,783

101,337

Sales and marketing

27,886

25,392

52,480

47,713

General and administrative

28,534

26,441

55,724

53,897

Total stock-based compensation

$      136,803

$      121,966

$      256,062

$      234,176

VEEVA SYSTEMS INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(In thousands)

(Unaudited)

Six months ended July 31,

2026

2025

Cash flows from operating activities

Net income

$     534,365

$     428,499

Adjustments to reconcile net income to net cash provided by operating activities:

Depreciation and amortization

22,458

19,948

Reduction of lease right-of-use assets

7,038

6,316

Accretion of discount on short-term investments

(2,841)

(4,535)

Stock-based compensation

256,062

234,176

Amortization of deferred costs

9,805

8,205

Deferred income taxes

26,529

31,699

Other, net

(1,127)

(1,414)

Changes in operating assets and liabilities:

Accounts receivable

768,314

593,032

Unbilled accounts receivable

(18,361)

(9,587)

Deferred costs

(7,679)

(7,721)

Prepaid expenses and other current and long-term assets

(21,394)

(21,232)

Accounts payable

(652)

3,361

Accrued expenses and other current liabilities

(1,578)

23,763

Income tax payable

(3,945)

(5,362)

Deferred revenue

(200,001)

(180,888)

Lease liabilities

(4,426)

(5,300)

Other long-term liabilities

3,258

2,631

Net cash provided by operating activities

1,365,825

1,115,591

Cash flows from investing activities

Purchases of short-term investments

(1,706,632)

(1,452,857)

Maturities and sales of short-term investments

1,345,987

1,023,691

Long-term assets

(9,773)

(12,213)

Acquisitions, net of cash acquired

(81,833)

—

Net cash used in investing activities

(452,251)

(441,379)

Cash flows from financing activities

Proceeds from exercise of common stock options

17,143

182,297

Repurchases of common stock

(472,673)

—

Taxes paid related to net share settlement of equity awards

(66,304)

(46,228)

Net cash (used in) provided by financing activities

(521,834)

136,069

Effect of exchange rate changes on cash, cash equivalents, and restricted cash

(831)

1,365

Net change in cash, cash equivalents, and restricted cash

390,909

811,646

Cash, cash equivalents, and restricted cash at beginning of period

1,423,412

1,120,963

Cash, cash equivalents, and restricted cash at end of period

$   1,814,321

$   1,932,609

Supplemental disclosures of other cash flow information:

Excess tax (deficiency) benefit from employee stock plans

$        (824)

$      15,610

Non-GAAP Financial Measures

In Veeva's public disclosures, Veeva has provided non-GAAP measures, which it defines as financial information that has not been prepared in accordance with generally accepted accounting principles in the United States, or GAAP. In addition to its GAAP measures, Veeva uses these non-GAAP financial measures internally for budgeting and resource allocation purposes and in analyzing its financial results. For the reasons set forth below, Veeva believes that excluding the following items provides information that is helpful in understanding its operating results, evaluating its future prospects, comparing its financial results across accounting periods, and comparing its financial results to its peers, many of which provide similar non-GAAP financial measures.

Excess tax benefit (deficiency). Excess tax benefits (deficiencies) from employee stock plans are dependent on previously agreed-upon equity grants to our employees, vesting of those grants, stock price, and exercise behavior of our employees, which can fluctuate from quarter to quarter. Because these fluctuations are not directly related to our business operations, Veeva finds it useful to exclude excess tax benefits (deficiencies) when assessing the level of cash provided by operating activities. Given the nature of the excess tax benefits (deficiencies), Veeva believes excluding it allows investors to make meaningful comparisons between our operating cash flows from quarter to quarter and those of other companies. Stock-based compensation expenses. Veeva excludes stock-based compensation expenses primarily because they are non-cash expenses that Veeva excludes from its internal management reporting processes. Veeva's management also finds it useful to exclude these expenses when they assess the appropriate level of various operating expenses and resource allocations when budgeting, planning and forecasting future periods. Moreover, because of varying available valuation methodologies, subjective assumptions and the variety of award types that companies can use, Veeva believes excluding stock-based compensation expenses allows investors to make meaningful comparisons between our recurring core business operating results and those of other companies. Amortization of purchased intangibles. Veeva incurs amortization expense for purchased intangible assets in connection with acquisitions of certain businesses and technologies. Amortization of intangible assets is a non-cash expense and is inconsistent in amount and frequency because it is significantly affected by the timing, size of acquisitions and the inherent subjective nature of purchase price allocations. Because these costs have already been incurred and cannot be recovered, and are non-cash expenses, Veeva excludes these expenses for its internal management reporting processes. Veeva's management also finds it useful to exclude these charges when assessing the appropriate level of various operating expenses and resource allocations when budgeting, planning and forecasting future periods. Investors should note that the use of intangible assets contributed to Veeva's revenues earned during the periods presented and will contribute to Veeva's future period revenues as well. Litigation settlement-related charges. We exclude certain costs related to litigation settlements, including outcome-based payments to the law firms that represented us, because they are non-recurring and outside the ordinary course of business. Because these costs are unrelated to our day-to-day business operations, we believe excluding them enables more consistent evaluation of our operating results. Income tax effects on the difference between GAAP and non-GAAP costs and expenses. The income tax effects that are excluded relate to the imputed tax impact on the difference between GAAP and non-GAAP costs and expenses due to stock-based compensation and purchased intangibles for GAAP and non-GAAP measures. There are limitations to using non-GAAP financial measures because non-GAAP financial measures are not prepared in accordance with GAAP and may be different from non-GAAP financial measures provided by other companies. The non-GAAP financial measures are limited in value because they exclude certain items that may have a material impact upon our reported financial results. In addition, they are subject to inherent limitations as they reflect the exercise of judgments by Veeva's management about which items are adjusted to calculate its non-GAAP financial measures. Veeva compensates for these limitations by analyzing current and future results on a GAAP basis as well as a non-GAAP basis and also by providing GAAP measures in its public disclosures.

Non-GAAP financial measures should not be considered in isolation from, or as a substitute for, financial information prepared in accordance with GAAP. Veeva encourages its investors and others to review its financial information in its entirety, not to rely on any single financial measure to evaluate its business, and to view its non-GAAP financial measures in conjunction with the most directly comparable GAAP financial measures. A reconciliation of GAAP to the non-GAAP financial measures has been provided in the tables below.

VEEVA SYSTEMS INC.

RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL MEASURES

(Dollars in thousands)

(Unaudited)

The following tables reconcile the specific items excluded from GAAP metrics in the calculation of non-GAAP metrics for the periods shown below:

Reconciliation of Net Cash Provided by Operating Activities (GAAP basis to non-GAAP basis)

Three months ended July 31,

Six months ended July 31,

2026

2025

2026

2025

Net cash provided by operating activities on a GAAP basis

$    238,709

$    238,433

$  1,365,825

$  1,115,591

Excess tax (benefit) deficiency from employee stock plans

(3,268)

(13,031)

824

(15,610)

Net cash provided by operating activities on a non-GAAP basis

$    235,441

$    225,402

$  1,366,649

$  1,099,981

Net cash used in investing activities on a GAAP basis

$    (63,540)

$   (389,272)

$   (452,251)

$   (441,379)

Net cash (used in) provided by financing activities on a GAAP basis

$   (259,308)

$    115,689

$   (521,834)

$    136,069

Reconciliation of Financial Measures (GAAP basis to non-GAAP basis)

Three months ended July 31,

Six months ended July 31,

2026

2025

2026

2025

Cost of subscription revenues on a GAAP basis

$    105,677

$     93,830

$    204,780

$    172,176

Stock-based compensation expense

(2,224)

(1,941)

(3,985)

(3,656)

Amortization of purchased intangibles

(1,072)

(1,046)

(1,746)

(2,058)

Cost of subscription revenues on a non-GAAP basis

$    102,381

$     90,843

$    199,049

$    166,462

Gross margin on subscription revenues on a GAAP basis

86.2 %

85.8 %

86.3 %

86.7 %

Stock-based compensation expense

0.3

0.3

0.3

0.3

Amortization of purchased intangibles

0.1

0.1

0.1

0.1

Gross margin on subscription revenues on a non-GAAP basis

86.6 %

86.2 %

86.7 %

87.1 %

Cost of professional services and other revenues on a GAAP basis

$    126,335

$    101,423

$    248,156

$    196,901

Stock-based compensation expense

(15,939)

(14,804)

(30,090)

(27,573)

Amortization of purchased intangibles

—

(139)

—

(273)

Cost of professional services and other revenues on a non-GAAP basis

$    110,396

$     86,480

$    218,066

$    169,055

Gross margin on professional services and other revenues on a GAAP basis

21.6 %

21.9 %

21.0 %

22.5 %

Stock-based compensation expense

9.9

11.4

9.5

10.8

Amortization of purchased intangibles

—

0.1

—

0.2

Gross margin on professional services and other revenues on a non-GAAP basis

31.5 %

33.4 %

30.5 %

33.5 %

Gross profit on a GAAP basis

$    695,951

$    593,828

$  1,357,975

$  1,179,047

Stock-based compensation expense

18,163

16,745

34,075

31,229

Amortization of purchased intangibles

1,072

1,185

1,746

2,331

Gross profit on a non-GAAP basis

$    715,186

$    611,758

$  1,393,796

$  1,212,607

Gross margin on total revenues on a GAAP basis

75.0 %

75.3 %

75.0 %

76.2 %

Stock-based compensation expense

2.0

2.1

1.9

2.0

Amortization of purchased intangibles

0.1

0.1

0.1

0.1

Gross margin on total revenues on a non-GAAP basis

77.1 %

77.5 %

77.0 %

78.3 %

Research and development expense on a GAAP basis

$    222,918

$    192,677

$    431,241

$    376,710

Stock-based compensation expense

(62,220)

(53,388)

(113,783)

(101,337)

Amortization of purchased intangibles

(270)

—

(270)

—

Research and development expense on a non-GAAP basis

$    160,428

$    139,289

$    317,188

$    275,373

VEEVA SYSTEMS INC.

RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL MEASURES (continued)

(Dollars in thousands, except per share data)

(Unaudited)

Three months ended July 31,

Six months ended July 31,

2026

2025

2026

2025

Sales and marketing expense on a GAAP basis

$    126,701

$    109,439

$    237,818

$    208,067

Stock-based compensation expense

(27,886)

(25,392)

(52,480)

(47,713)

Amortization of purchased intangibles

(2,720)

(2,890)

(5,051)

(5,685)

Sales and marketing expense on a non-GAAP basis

$     96,095

$     81,157

$    180,287

$    154,669

General and administrative expense on a GAAP basis

$     71,314

$     95,804

$    140,786

$    164,630

Stock-based compensation expense

(28,534)

(26,441)

(55,724)

(53,897)

Litigation settlement-related charges

—

(30,627)

—

(30,627)

General and administrative expense on a non-GAAP basis

$     42,780

$     38,736

$     85,062

$     80,106

Operating expense on a GAAP basis

$    420,933

$    397,920

$    809,845

$    749,407

Stock-based compensation expense

(118,640)

(105,221)

(221,987)

(202,947)

Amortization of purchased intangibles

(2,990)

(2,890)

(5,321)

(5,685)

Litigation settlement-related charges

—

(30,627)

—

(30,627)

Operating expense on a non-GAAP basis

$    299,303

$    259,182

$    582,537

$    510,148

Operating income on a GAAP basis

$    275,018

$    195,908

$    548,130

$    429,640

Stock-based compensation expense

136,803

121,966

256,062

234,176

Amortization of purchased intangibles

4,062

4,075

7,067

8,016

Litigation settlement-related charges

—

30,627

—

30,627

Operating income on a non-GAAP basis

$    415,883

$    352,576

$    811,259

$    702,459

Operating margin on a GAAP basis

29.6 %

24.8 %

30.3 %

27.8 %

Stock-based compensation expense

14.7

15.5

14.1

15.1

Amortization of purchased intangibles

0.5

0.5

0.4

0.5

Litigation settlement-related charges

—

3.9

—

2.0

Operating margin on a non-GAAP basis

44.8 %

44.7 %

44.8 %

45.4 %

Net income on a GAAP basis

$    273,429

$    200,309

$    534,365

$    428,499

Stock-based compensation expense

136,803

121,966

256,062

234,176

Amortization of purchased intangibles

4,062

4,075

7,067

8,016

Litigation settlement-related charges

—

30,627

—

30,627

Income tax effect on non-GAAP adjustments(6)

(26,882)

(23,572)

(38,945)

(40,085)

Net income on a non-GAAP basis

$    387,412

$    333,406

$    758,549

$    661,234

Diluted net income per share on a GAAP basis

$        1.66

$        1.19

$        3.22

$        2.56

Stock-based compensation expense

0.83

0.73

1.54

1.40

Amortization of purchased intangibles

0.02

0.02

0.04

0.05

Litigation settlement-related charges

—

0.18

—

0.18

Income tax effect on non-GAAP adjustments(6)

(0.16)

(0.13)

(0.23)

(0.24)

Diluted net income per share on a non-GAAP basis

$        2.35

$        1.99

$        4.57

$        3.95

________________________
(6) For the three and six months ended July 31, 2026 and 2025, management used an estimated annual effective non-GAAP tax rate of 21.0%.

SOURCE Veeva Systems

American Capital Management Inc. purchased a new stake in shares of Veeva Systems Inc. (NYSE:VEEV – Free Report) during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor purchased 196,848 shares of the technology company’s stock, valued at approximately $34,935,000. Veeva Systems makes up about 1.6% of American Capital Management Inc.’s investment portfolio, making the stock its 26th biggest position. American Capital Management Inc. owned about 0.12% of Veeva Systems as of its most recent SEC filing.

Other institutional investors have also bought and sold shares of the company. Sivia Capital Partners LLC increased its stake in Veeva Systems by 225.9% in the second quarter. Sivia Capital Partners LLC now owns 3,122 shares of the technology company’s stock worth $899,000 after purchasing an additional 2,164 shares during the period. Bank of Nova Scotia grew its holdings in shares of Veeva Systems by 44.5% in the second quarter. Bank of Nova Scotia now owns 5,866 shares of the technology company’s stock worth $1,689,000 after purchasing an additional 1,806 shares during the last quarter. NewEdge Advisors LLC grew its holdings in shares of Veeva Systems by 34.6% in the second quarter. NewEdge Advisors LLC now owns 8,832 shares of the technology company’s stock worth $2,543,000 after purchasing an additional 2,272 shares during the last quarter. Treasurer of the State of North Carolina increased its stake in Veeva Systems by 2.2% in the 2nd quarter. Treasurer of the State of North Carolina now owns 68,950 shares of the technology company’s stock worth $19,856,000 after buying an additional 1,452 shares during the period. Finally, Diversify Wealth Management LLC increased its stake in Veeva Systems by 5.3% in the 2nd quarter. Diversify Wealth Management LLC now owns 11,399 shares of the technology company’s stock worth $3,140,000 after buying an additional 575 shares during the period. Institutional investors own 88.20% of the company’s stock.

Trending Headlines about Veeva Systems Here are the key news stories impacting Veeva Systems this week:

Positive Sentiment: Veeva reported second-quarter revenue of approximately $928 million, up 17.6% year over year and above the $905.4 million consensus estimate. Subscription revenue rose 16% to $766.8 million. Veeva Announces Fiscal 2027 Second Quarter Results Positive Sentiment: Adjusted earnings reached $2.35 per share, exceeding the $2.22 consensus estimate and increasing from $1.99 a year earlier. The earnings and revenue beats were approximately 5.9% and 2.6%, respectively. Veeva Systems Q2 Earnings and Revenues Beat Estimates Positive Sentiment: Management issued above-consensus fiscal 2027 guidance, including revenue of about $3.7 billion versus a $3.6 billion estimate and EPS of $9.21 versus an $8.58 estimate. Third-quarter revenue guidance of $932 million-$935 million and EPS guidance of $2.33-$2.34 also topped analyst forecasts. Positive Sentiment: Biogen and Regeneron each committed to adopting Veeva Vault CRM globally. The wins reinforce Veeva’s competitive position in life-sciences customer relationship management and may support future subscription growth. Veeva Vault CRM Selected by Regeneron Veeva Vault CRM Selected by Biogen Neutral Sentiment: Piper Sandler initiated coverage, while Needham reaffirmed its Buy rating. These actions add analyst visibility but provide limited new information without detailed price targets or estimates. Neutral Sentiment: Despite the improving outlook, Veeva trades at a relatively elevated valuation, with a reported price-to-earnings ratio above 43. Future gains may therefore depend on continued execution and strong growth. Insider Activity In other Veeva Systems news, insider Thomas D. Schwenger sold 36,000 shares of the business’s stock in a transaction that occurred on Thursday, August 13th. The stock was sold at an average price of $250.23, for a total value of $9,008,280.00. Following the completion of the transaction, the insider directly owned 19,449 shares of the company’s stock, valued at approximately $4,866,723.27. The trade was a 64.92% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 10.60% of the stock is currently owned by company insiders. Analyst Ratings Changes A number of brokerages recently issued reports on VEEV. Evercore reiterated an “outperform” rating and issued a $185.00 price target on shares of Veeva Systems in a report on Thursday, June 4th. Wells Fargo & Company lifted their target price on Veeva Systems from $317.00 to $320.00 and gave the company an “overweight” rating in a research report on Thursday, June 4th. The Goldman Sachs Group lowered their target price on Veeva Systems from $190.00 to $165.00 and set a “sell” rating for the company in a report on Thursday, June 4th. Needham & Company LLC reissued a “buy” rating and set a $270.00 price target on shares of Veeva Systems in a research report on Monday. Finally, Citigroup raised their price target on Veeva Systems from $176.00 to $190.00 and gave the company a “neutral” rating in a research note on Thursday, June 4th. Nineteen analysts have rated the stock with a Buy rating, eight have given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $258.08.

Check Out Our Latest Stock Analysis on VEEV

Veeva Systems Stock Down 0.8% VEEV opened at $244.72 on Thursday. The company has a market cap of $39.75 billion, a P/E ratio of 43.62, a price-to-earnings-growth ratio of 1.06 and a beta of 0.92. The firm’s 50-day moving average price is $203.41 and its 200-day moving average price is $183.04. Veeva Systems Inc. has a 52-week low of $148.05 and a 52-week high of $310.50.

Veeva Systems (NYSE:VEEV – Get Free Report) last announced its quarterly earnings data on Wednesday, August 26th. The technology company reported $2.35 earnings per share for the quarter, beating analysts’ consensus estimates of $2.22 by $0.13. The firm had revenue of $927.96 million for the quarter, compared to analyst estimates of $905.38 million. Veeva Systems had a net margin of 28.37% and a return on equity of 13.72%. The business’s quarterly revenue was up 17.6% compared to the same quarter last year. During the same period in the previous year, the company earned $1.99 earnings per share. Veeva Systems has set its FY 2027 guidance at 9.210-9.210 EPS and its Q3 2027 guidance at 2.330-2.340 EPS. On average, research analysts anticipate that Veeva Systems Inc. will post 6.65 EPS for the current fiscal year.

Veeva Systems Profile (Free Report)

Veeva Systems (NYSE: VEEV) is a cloud software company that develops industry-specific applications and data solutions for the global life sciences sector. Founded in 2007 and headquartered in Pleasanton, California, Veeva focuses on helping pharmaceutical, biotechnology, medical device and consumer health companies manage regulated content, clinical and regulatory processes, quality systems, and commercial operations in a compliant, cloud-native environment. The company completed its initial public offering in 2013 and has since expanded its product suite and international footprint.

Veeva’s product portfolio centers on its Vault platform and related application suites, which provide content and data management, clinical trial and regulatory workflows, quality management, and structured commercial capabilities such as customer relationship management and promotional content management.

Read More Five stocks we like better than Veeva Systems Williams-Sonoma’s Quarter Gave Bulls More Than Just a Beat-and-Raise Alcoa’s Gallium Project Opens a New Door Beyond Aluminum Oura’s $16 Billion IPO Could Put a New Price on Wearable Tech Can Tesla’s Flying Roadster Distract From Its Real Risks?

Receive News & Ratings for Veeva Systems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Veeva Systems and related companies with MarketBeat.com's FREE daily email newsletter.

It has been about a month since the last earnings report for Veeva Systems (VEEV - Free Report) . Shares have added about 7.9% in that time frame, outperforming the S&P 500.

But investors have to be wondering, will the recent positive trend continue leading up to its next earnings release, or is Veeva due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important catalysts.

Veeva Systems Q1 Earnings & Revenues Beat, Operating Margin RiseVeeva Systems reported adjusted earnings per share of $2.24 for the first quarter of fiscal 2027, which increased 13.7% from the year-ago figure of $1.74. Adjusted earnings per share beat the Zacks Consensus Estimate by 5.2%.

GAAP earnings per share in the fiscal first quarter was $1.57, up 14.6% from the year-ago period’s $1.37.

VEEV’s Q1 Revenue DetailsIn the quarter under review, the company’s revenues totaled $882.9 million, beating the Zacks Consensus Estimate by 2.9%. On a year-over-year basis, the top line improved 16.3%.

The fiscal first-quarter top line was driven by Veeva Systems’ robust segmental performance.

Segmental Analysis of VEEVVeeva Systems derives revenues from two operating segments: Subscription services and Professional services and other.

In the fiscal first quarter, Subscription services revenues improved 15% from the year-ago quarter to $730.2 million. Per management, this uptick was driven by both its established and newer solutions.

Professional services and other revenues increased 22.9% year over year to $152.8 million.

Q1 Margin Performance by VEEVIn the quarter under review, Veeva Systems’ gross profit improved 13.1% year over year to $662 million. However, the gross margin contracted 220 basis points (bps) to 74.9%.

Sales and marketing expenses increased 12.7% year over year to $111.1 million. Research and development (R&D) expenses rose 13.2% year over year to $208.3 million, while general and administrative expenses increased 0.9% year over year to $69.5 million. Total operating expenses of $388.9 million increased 10.6% year over year.

Operating profit totaled $273.1 million, which increased 16.8% from the prior-year quarter. The operating margin in the fiscal first quarter expanded 20 bps to 30.9%.

VEEV’s Financial PositionThe company exited first-quarter fiscal 2027 with cash and cash equivalents and short-term investments of $7.31 billion compared with $6.56 billion at the fiscal fourth quarter of 2026-end.

Net cash provided by operating activities at the end of the quarter was $1.13 billion compared with $877.2 million a year ago.

Q2 & FY27 Guidance Provided by VEEVVeeva Systems has issued its financial outlook for the fiscal second quarter and fiscal 2027.

For the fiscal second quarter, the company expects total revenues between $902 million and $905 million. The Zacks Consensus Estimate is currently pegged at $886.8 million.

Subscription revenues are estimated to be approximately $754 million, and revenues for Professional services and other are expected to be in the range of $148-$151 million for the fiscal second quarter.

For the fiscal second quarter, adjusted earnings per share is anticipated to be between $2.21 and $2.22. The Zacks Consensus Estimate is pegged at $2.19.

Veeva Systems now expects revenues for fiscal 2027 between $3,635 million and $3,645 million. The Zacks Consensus Estimate is currently pegged at $3.59 billion.

For fiscal 2027, Subscription revenues are now expected to be approximately $3,060 million. This consists of Commercial Solutions’ subscription revenues of around $1,395 million and R&D Solutions’ subscription revenues of approximately $1,665 million.

Professional services and other revenues for fiscal 2027 are now expected to be between $575 million and $580 million.

Adjusted earnings per share for fiscal 2027 is now expected to be approximately $9.05. The Zacks Consensus Estimate is pegged at $8.86.

How Have Estimates Been Moving Since Then?In the past month, investors have witnessed a upward trend in estimates revision.

VGM ScoresAt this time, Veeva has a nice Growth Score of B, though it is lagging a lot on the Momentum Score front with a D. Charting a somewhat similar path, the stock was allocated a score of C on the value side, putting it in the middle 20% for value investors.

Overall, the stock has an aggregate VGM Score of C. If you aren't focused on one strategy, this score is the one you should be interested in.

OutlookEstimates have been broadly trending upward for the stock, and the magnitude of these revisions looks promising. Interestingly, Veeva has a Zacks Rank #3 (Hold). We expect an in-line return from the stock in the next few months.

Key Takeaways Veeva launched EHS within Quality Cloud to help sites manage operational and environmental risks.VEEV shares fell 2% after the news, with the stock down 29.2% year to date.Veeva EHS automates incident reporting, investigations and compliance workflows on one platform. Veeva Systems (VEEV - Free Report) recently announced the launch of Veeva EHS, a new environmental, health and safety application within its Veeva Quality Cloud. The solution is designed to help manufacturing and testing sites proactively identify, manage and mitigate operational and environmental risks while strengthening global compliance readiness.

Management stated that Veeva EHS delivers an advanced and automated approach to environmental, health and safety processes. It enables EHS teams to free up time and ensures quick and accurate execution. The company believes organizations replacing legacy EHS systems with a unified platform will gain real-time transparency into leading indicators of risk for more informed decisions and a proactive approach to prevention.

Veeva EHS is expected to be available to early adopters in August 2026.

Likely Trend of VEEV Stock Following the NewsFollowing the announcement, VEEV shares lost 2% at yesterday’s closing. Year to date, the stock has declined 29.2%, underperforming the industry’s 15.2% fall and the S&P 500’s 7.3% rise.

The launch of Veeva EHS is expected to strengthen Veeva’s position in the EHS software market by expanding its Quality Cloud portfolio. The unified platform can drive higher customer adoption, improve cross-selling opportunities and increase recurring revenues. Its automation, real-time risk visibility and integrated compliance capabilities also enhance Veeva's competitive advantage over legacy EHS solution providers, supporting long-term business growth.

VEEV currently has a market capitalization of $26.21 billion.

Image Source: Zacks Investment Research

More on Veeva EHSVeeva EHS enables organizations to report safety incidents in real time, manage investigations from start to finish and automate compliance workflows within a single platform. The solution integrates with Veeva QMS and Veeva Training, allowing safety events to automatically create quality deviations and assign relevant training. This eliminates duplicate data entry, streamlines workflows and helps organizations maintain compliance.

According to Bobbie Grant, Global Senior EHS Manager at Thermo Fisher Scientific, a modern EHS platform with unified data and a seamless user experience across the entire EHS workflow can significantly improve site efficiency. Grant added that Veeva provides an advanced solution that can maintain data integrity and provide the foundation for AI-driven capabilities to reduce risk over time.

Industry Prospects Favoring the MarketGoing by the data provided by Research and Markets, the environmental health and safety (EHS) software market is valued at $8.9 billion in 2026 and is expected to witness a CAGR of 8.1% through 2030.

Factors like the stringent regulatory requirements that healthcare and life science organizations must navigate, digital transformation initiatives in healthcare and life sciences, a growing focus on workplace safety and risk reduction, and the integration of AI and machine learning are boosting the market’s growth.

Other NewsVeeva recently acquired Copli, a pioneer in agentic medical, legal and regulatory (MLR) solutions for the life sciences industry. Copli is available as Veeva Falcon MLR, an agentic MLR solution that significantly accelerates content review with the potential to eliminate 70% or more of manual MLR labor within five years.

VEEV’s Zacks Rank & Key PicksCurrently, VEEV has a Zacks Rank #3 (Hold).

Some better-ranked stocks from the broader medical space are BrightSpring Health (BTSG - Free Report) , Globus Medical (GMED - Free Report) and Intuitive Surgical (ISRG - Free Report) .

BrightSpring Health, currently sporting a Zacks Rank #1 (Strong Buy), reported first-quarter 2026 adjusted earnings per share (EPS) of 39 cents, which beat the Zacks Consensus Estimate by 34.5%. Revenues of $3.61 billion surpassed the Zacks Consensus Estimate by 8.35%. You can see the complete list of today’s Zacks #1 Rank stocks here.

BrightSpring Health has an estimated long-term earnings growth rate of 46.5%. BTSG’s earnings surpassed estimates in three of the trailing four quarters and missed once, the average surprise being 14.6%.

Globus Medical, currently carrying a Zacks Rank #2 (Buy), reported a first-quarter 2026 adjusted EPS of $1.12, which surpassed the Zacks Consensus Estimate by 22.1%. Revenues of $759.9 million beat the Zacks Consensus Estimate by 4.0%.

GMED has an estimated long-term earnings growth rate of 10.2%. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 26.3%.

Intuitive Surgical, carrying a Zacks Rank #2 at present, reported first-quarter 2026 adjusted EPS of $2.50, which beat the Zacks Consensus Estimate by 20.2%. Revenues of $2.77 billion surpassed the Zacks Consensus Estimate by 6.2%.

Intuitive Surgical has a long-term estimated growth rate of 14.3%. ISRG’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 16.8%.